/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test,.
New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development
/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test,.
/PRNewswire/ Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.